William Blair initiated coverage of Cencora (COR) with a Market Perform rating. Cencora is positioned to capitalize on a structurally favorable demand backdrop supported by demographic tailwinds and rising adoption of specialty medicines, the analyst tells investors in a research note. However, Blair believes Cardinal Health is better positioned to drive superior returns.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
- Cencora price target lowered to $360 from $420 at Evercore ISI
- Cencora to Acquire EyeSouth Retina Business for Expansion
- Cencora signs agreement to acquire EyeSouth Partners’ retina business for $1.1B
- Midday Fly By: Nvidia bullish on AI revenue, MasterCard to acquire BVNK
- Cencora CFO Retirement Announced, Financial Guidance Reaffirmed